Dashboard
Manage Tickers

ATXS Astria Therapeutics, Inc.

Nasdaq astriatx.com


$ 12.61 $ 0.00 (0 %)    

Thursday, 06-Nov-2025 08:00:11 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 624.48 $ 0.00 (0 %)
DIA $ 473.47 $ 0.00 (0 %)
SPY $ 678.88 $ 0.00 (0 %)
TLT $ 89.16 $ 0.00 (0 %)
GLD $ 368.51 $ 0.00 (0 %)
$ 12.62
$ 12.30
$ 12.22 x 25
$ 12.70 x 56
-- - --
$ 3.56 - $ 12.72
1,428,993
na
732.03M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-04-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-10-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

astria-therapeutics-alpha-star-phase-1b2-study-evaluating-navenibart-monoclonal-antibody-inhibitor-in-hereditary-angioedema-participants-shows-robust-attack-rate-reduction-favorable-safety-tolerability-profile
Astria Therapeutics ALPHA-STAR Phase 1b/2 ...
11/06/2025 13:14:41

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

astria-therapeutics-to-present-final-results-from-alpha-star-phase-1b2-trial-of-navenibart-in-people-living-with-hae-at-acaai-annual-scientific-meeting
Astria Therapeutics To Present Final Resul...
10/31/2025 12:06:26

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

this-verisk-analytics-analyst-turns-bearish-here-are-top-5-downgrades-for-thursday
This Verisk Analytics Analyst Turns Bearis...
10/16/2025 13:01:42

hc-wainwright--co-downgrades-astria-therapeutics-to-neutral
HC Wainwright & Co. Downgrades Astria Ther...
10/16/2025 10:47:44

HC Wainwright & Co. analyst Joseph Pantginis downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Neutral.

wedbush-downgrades-astria-therapeutics-to-neutral-lowers-price-target-to-13
Wedbush Downgrades Astria Therapeutics to ...
10/15/2025 15:15:04

Wedbush analyst Laura Chico downgrades Astria Therapeutics (NASDAQ:ATXS) from Outperform to Neutral and lowers the price tar...

jmp-securities-downgrades-astria-therapeutics-to-market-perform
JMP Securities Downgrades Astria Therapeut...
10/15/2025 11:18:47

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics (NASDAQ:ATXS) from Market Outperform to Market Perform.

jefferies-downgrades-astria-therapeutics-to-hold-lowers-price-target-to-13
Jefferies Downgrades Astria Therapeutics t...
10/14/2025 18:18:58

Jefferies analyst Eun Yang downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Hold and lowers the price target from $3...

dow-jumps-over-300-points-citigroup-posts-upbeat-earnings
Dow Jumps Over 300 Points; Citigroup Posts...
10/14/2025 17:09:06

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate
BioCryst Says Astria Therapeutics $700 Mil...
10/14/2025 16:20:52

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

dominos-pizza-posts-upbeat-results-joins-astria-therapeutics-albertsons-companies-polaris-and-other-big-stocks-moving-higher-on-tuesday
Domino's Pizza Posts Upbeat Results, Joins...
10/14/2025 14:15:51

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

trading-halt-halt-status-updated-at-71500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:15:...
10/14/2025 11:15:04

Core News & Articles
BioCryst to Acquire Astria Therapeutics fo...
10/14/2025 11:02:17

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
10/14/2025 10:55:04

astria-therapeutics-initiates-phase-3-orbit-expanse-trial-of-navenibart-for-hae-announced-earlier-today
Astria Therapeutics Initiates Phase 3 ORBI...
10/08/2025 14:09:30

astria-therapeutics-to-present-new-data-on-its-drug-candidate-navenibart-at-2025-haei-regional-conference-emea-in-rome-italy
Astria Therapeutics To Present New Data On...
10/03/2025 12:04:05

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

astria-therapeutics-begins-opening-clinical-trial-sites-in-eu-and-may-begin-screening-participants-for-phase-3-alpha-orbit-trial-of-navenibart-for-hae-treatment
Astria Therapeutics Begins Opening Clinica...
10/02/2025 12:06:52

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

hc-wainwright--co-maintains-buy-on-astria-therapeutics-raises-price-target-to-20
HC Wainwright & Co. Maintains Buy on Astri...
09/17/2025 15:46:05

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and raises the price...

cantor-fitzgerald-reiterates-overweight-on-astria-therapeutics-maintains-49-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/17/2025 14:12:23

Cantor Fitzgerald analyst Steven Seedhouse reiterates Astria Therapeutics (NASDAQ:ATXS) with a Overweight and maintains $49 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION